Monthly Archives: November 2010
Clinical Data sells assets to Transgenomic
Clinical Data has announced that it has signed a definitive asset purchase agreement with Transgenomic to sell its genetic and pharmacogenomic testing and biomarker development business for approximately $15.4 million, including $6 million in cash, a three-year promissory note for … Continue reading
Filed under acquisitions
Sutro Biopharma raises $36.50 million
OnBioVC reports that Sutro Biopharma, a preclinical-stage biopharmaceutical company focused on partnering and developing proprietary protein therapeutics that have site directed modifications, has closed a $36.50 million Series C financing. Participants include Skyline Ventures, Lilly Ventures, Amgen Ventures, SV Life … Continue reading
Filed under funding
Pfizer and Protalix BioTherapeutics submit MAA to EMA
Pfizer and Protalix BioTherapeutics have jointly reported the submission of a Marketing Authorisation Application to the European Medicines Agency for taliglucerase alfa for the treatment of Gaucher disease. Pfizer and Protalix signed an agreement in November 2009 to develop and … Continue reading
Filed under alliances
Thallion Pharmaceuticals and LFB Biotechnologies initiate Stec trails
Thallion Pharmaceuticals and LFB Biotechnologies have announced the initiation of a Phase Ii Trial in South America evaluating Shigamabs as a treatment for Shigatoxin-Producing E. Coli (Stec) infections. The timing of the trial coincides with the seasonal high period for … Continue reading
Filed under alliances
UBC licenses drug delivery technology to Covidien
The University of British Columbia and the Centre for Drug Research and Development have announced that Covidien has licensed a drug-delivery platform technology invented by a UBC researcher, Dr Pieter Cullis. After the initial discovery at UBC, the project was … Continue reading
Filed under licensing
Binnopharm and GlaxoSmithKline sign Russian vaccine pact
Russian pharmaceutical company Binnopharm and GlaxoSmithKline have signed an agreement on transferring technologies and antigen supplies to produce innovative vaccines in Russia. Under the agreement, the parties intend to create a joint scientific and research center in Russia. GlaxoSmithKline will … Continue reading
Filed under alliances
MDxHealth licenses PCR technology to Takara Bio
MDxHealth has announced that it has granted a non-exclusive worldwide license for its patented methylation specific PCR technology to Takara Bio. Under the agreement, Takara has licensed the use of MDxHealth’s MSP technology, a widely applied methylation technology, for the … Continue reading
Filed under licensing
Pfizer receives Japanese approval for Lyrica
Pfizer has announced that it has received approval from Japan’s Ministry of Health, Labor and Welfare to sell its painkiller Lyrica to treat peripheral neuropathic pain. The drug is the first in Japan approved for treatment of the disease. Pfizer … Continue reading
Filed under alliances
GlaxoSmithKline increase its shareholding in Theravance
Theravance and GlaxoSmithKline have announced today that GSK will increase its shareholding in Theravance by 50% taking its stake to approximately 19% of the total outstanding capital stock of Theravance.
Filed under funding
Oculus Innovative Sciences and Onset Therapeutics sign dermatitis alliance
Oculus Innovative Sciences and Onset Therapeutics have entered into an agreement to commercialize dermatology products in the US. Their initial collaboration will target atopic dermatitis and related conditions.
Filed under alliances
